Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE

-- Poster Session 4213 on Monday, March 6 from 9:45 am to 10:45 am

NEW YORK, March 01, 2017 -- Attune Pharmaceuticals, a biotechnology company focused on the discovery and development of novel oral small molecule therapeutics for treatment of rare diseases, announced today that the Company will present new data for ATN-249 in a late-breaking poster at the 2017 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2017).

The poster presentation highlights potency, selectivity, pharmacokinetic, and safety attributes of ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment Hereditary Angioedema (HAE). Preclinical studies demonstrated ATN-249 was highly selective and potent at plasma kallikrein inhibition in both biochemical and contact activation assays. Pharmacokinetic data support once daily administration with a wide therapeutic index.

The poster will be presented at the Late Breaking Poster Session 4213 on Monday, March 6 from 9:45 am to 10:45 am in Georgia World Congress Center, Building B Exhibit Hall B2. Each poster will remain on display throughout the day until 6:00pm.

AAAAI 2017 will be held at Georgia World Congress Center, 285 Andrew Young International Blvd NW, Atlanta, GA, from Friday, March 3, 2017 through Monday, March 6, 2017.

Details for the poster presentation:
Title: Potency, Selectivity, and Exposure Evaluation of ATN-249, a New Oral Kallikrein Inhibitor for Hereditary Angioedema

Poster Number: L11

Downloadable copies of the abstract are available in the February 2017 online supplement to The Journal of Allergy and Clinical Immunology: http://www.jacionline.org/article/S0091-6749(16)32423-X/abstract

About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, potentially life-threatening disease characterized by acute skin and mucosal edema. It is caused by an autosomal dominant mutation of the SERPING1 or F12 genes, resulting in affected C1 inhibitor protein. Dysregulation of the C1 pathway from non-functional C1 inhibitor then causes upregulation of bradykinin production, leading to increased vascular permeability, recurrent abdominal pain, and swelling, which can be fatal if it involves the larynx. Current treatments are limited by route of administration and adverse events, since all conventional C1 pathway-specific drugs are administered intravenously or subcutaneously, and may be associated with drug-specific adverse effects.

About Attune Pharmaceuticals
Attune Pharmaceuticals is a pre-clinical stage biotechnology focused on the discovery and development of novel oral once-daily small molecule therapeutics for treatment of rare diseases. Attune Pharmaceuticals is currently developing 2 programs in rare diseases: Hereditary angioedema (HAE) and complement-mediated diseases. Attune Pharmaceuticals has identified ATN-249 as a lead candidate to treat HAE and will begin clinical testing in 2017.

About ATN-249’s Clinical Development Program
ATN-249 was designed as a novel, potent, selective, and orally-administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE) by blocking kallikrein-mediated production of bradykinin. Preclinical studies in both biochemical and contact activation assays have demonstrated that ATN-249 is highly selective and potent at plasma kallikrein inhibition. ATN-249 has been evaluated in several pharmacokinetic and toxicological studies in multiple species. Given its observed wide therapeutic window and once-daily dosing potential, these preclinical results suggest that ATN-249 may be a potent, safe, orally-administered plasma kallikrein inhibitor for the treatment of HAE.

Contact
Attune Pharmaceuticals
[email protected]